SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharma major Dr Reddy’s Laboratories Ltd has launched five new generic drugs in the US market in January 2009. The products launched were Levetiracetam tablets (the generic version of UCB Keppra) with annual sales of $1.1 billion in 2008, Omeprazole capsules (the generic version of AstraZeneca’s Prilosec DR) with annual sales of $168 million, and Lamotragine CD chewable tablets (generic version of GlaxoSmithKline’s Lamictal) which had annual sale of $87 million.

Besdies, Divalproex capsules and delayed release pellets (generic version of Abbott’s Depakote) with annual sales of $126 million and Lamotrigine tablets (generic version of GlaxoSmithKline’s Lamictal) with annual sales of $2.3 billion were also launched. These five products add additional breadth and depth to the company’s product portfolio.

crackcrack

Dr. Reddys Lab Share Price

1232.00 19.65 (1.62%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×